Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 2 · 33.3%

Abiraterone + ADT vs ADT only

Time to death from any cause · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to lower time to death from any cause compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.64 [0.56, 0.73]
2 studies · 2201 participants
High

Quality of life (Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life]) measured at 12 months · men with metastatic, hormone‐sensitive prostate cancer

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 838 participants
Moderate

Abiraterone + ADT vs ADT only

Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.34 [1.22, 1.47]
1 study · 1199 participants
High

Abiraterone + ADT vs ADT only

Time to death from prostate cancerMedian · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to lower time to death due to prostate cancer measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.58 [0.5, 0.68]
2 studies · 2201 participants
Moderate

Abiraterone + ADT vs ADT only

Time to progression · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to lower time to disease progression measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.35 [0.26, 0.49]
2 studies · 2097 participants
Moderate

Abiraterone + ADT vs ADT only

Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
1 study · 1199 participants
Moderate